Imagion Biosystems Limited Provides Update on Mercer Convertible Securities Conversion and Amendment
Imagion Biosystems Limited (ASX: IBX) has provided key updates on its Convertible Securities Agreement with Mercer Street Global Opportunity Fund, LLC (Mercer Street). As of 5 January 2026, the first tranche of convertible notes, valued at AU$1,650,000, has been fully converted into 3,048,484 ordinary shares, effectively extinguishing the First Tranche Notes.
Additionally, the terms of the second tranche notes, initially issued in June 2023 for AU$1,100,000, have been revised. The outstanding balance, now reduced to AU$558,000, will have a new maturity date of 28 February 2026. A payment of AU$300,000 is due by 8 January 2026, further reducing the balance. The amended terms ensure that any remaining balance will be converted into shares at the agreed Conversion Price prior to the maturity date. Imagion's Executive Chairman, Bob Proulx, thanked Mercer Street for their continued support, highlighting the progress achieved and the significance of the partnership in advancing the company’s technology.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Imagion Biosystems Limited Provides Update on Mercer Convertible Securities Conversion and Amendment
Imagion Biosystems Limited (ASX: IBX) has provided key updates on its Convertible Securities Agreement with Mercer Street Global Opportunity Fund, LLC (Mercer Street). As of 5 January 2026, the first tranche of convertible notes, valued at AU$1,650,000, has been fully converted into 3,048,484 ordinary shares, effectively extinguishing the First Tranche Notes.
Additionally, the terms of the second tranche notes, initially issued in June 2023 for AU$1,100,000, have been revised. The outstanding balance, now reduced to AU$558,000, will have a new maturity date of 28 February 2026. A payment of AU$300,000 is due by 8 January 2026, further reducing the balance. The amended terms ensure that any remaining balance will be converted into shares at the agreed Conversion Price prior to the maturity date. Imagion's Executive Chairman, Bob Proulx, thanked Mercer Street for their continued support, highlighting the progress achieved and the significance of the partnership in advancing the company’s technology.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au